Does Dupixent Cause Eye Problems?
Yes, Dupixent (dupilumab) can cause eye problems. Clinical trials and post-marketing reports link it to ocular adverse events in 10-22% of patients, including conjunctivitis (inflammation of the eye's outer membrane), dry eyes, keratitis (corneal inflammation), and blurred vision. These effects stem from dupilumab's mechanism as an IL-4/IL-13 inhibitor, which disrupts immune regulation in mucosal tissues like the eyes, leading to inflammation in susceptible patients.[1][2]
How Common Are Eye Issues with Dupixent?
In pivotal trials for atopic dermatitis:
- Conjunctivitis occurred in 10% of Dupixent users vs. 2% on placebo.
- Keratitis affected up to 4% in asthma trials.
Real-world data shows rates up to 22% for any ocular event, often mild but recurring in 5-10% of cases. Ophthalmologic monitoring is recommended for patients with pre-existing eye conditions.[1][3]
What Specific Eye Problems Do Patients Report?
Common issues include:
- Conjunctivitis (redness, itching, discharge).
- Dry eye disease.
- Blepharitis (eyelid inflammation).
- Iritis or uveitis (deeper eye inflammation, rarer).
- Visual disturbances like blurred vision or eye pain.
Severe cases may require steroids or dose adjustments; most resolve after stopping treatment.[2][4]
Why Does Dupixent Affect the Eyes?
Dupixent blocks IL-4 and IL-13 signaling, cytokines key to type 2 inflammation in skin, lungs, and eyes. This can unmask or worsen underlying ocular allergies or dry eye by altering tear film and goblet cell function. Patients with allergic conjunctivitis history face higher risk.[1][5]
How Do Doctors Manage Eye Side Effects?
- Routine eye exams before and during treatment.
- Artificial tears or anti-inflammatory drops for mild cases.
- Pause or discontinue Dupixent if severe (e.g., vision-threatening keratitis).
- Switch to alternatives if recurrent. Risk decreases after first few months.[3][6]
Can Eye Problems Be Prevented?
No guaranteed prevention, but:
- Screen for baseline dry eye or allergies.
- Use lubricating drops proactively.
- Early reporting improves outcomes—symptoms often appear within 1-3 months.[4]
How Does This Compare to Similar Drugs?
Dupixent has higher ocular risks than other biologics:
| Drug | Conjunctivitis Rate | Notes |
|------|---------------------|-------|
| Dupixent | 10-22% | Highest reported |
| Xolair (omalizumab) | <5% | Lower eye effects |
| Ebglyss (lebrikizumab) | 8-12% | Similar IL-13 blocker |
| Nemluvio (nemolizumab) | ~5% | Less common |
Patients switching from Dupixent often see eye issues resolve.[5][7]
Sources:
[1]: Dupixent Prescribing Information (FDA)
[2]: NEJM Trial Data on Ocular Events
[3]: JAAD Real-World Study
[4]: Ophthalmology Journal Review
[5]: DrugPatentWatch.com - Dupixent Patents & Side Effects
[6]: Sanofi/Regeneron Safety Updates
[7]: Comparative Biologics Analysis (Lancet)